Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00731263 · ClinicalTrials.gov registry record · Phase 1
A Study of Tor Kinase Inhibitor in Advanced Tumors
A Phase 1 study of Solid Tumors, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 4
- Study locations
NCT00731263: Completed Phase 1 study of Solid Tumors, sponsored by AstraZeneca.
NCT00731263 is a Phase 1 study of Solid Tumors that has completed, run by AstraZeneca. The registered enrollment target is 64 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00731263, a Phase 1 study of Solid Tumors, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.
Conditions Studied
Interventions
- DRUG AZD8055
Study Locations (4)
New York
- Research Site - New York
Texas
- Research Site - Houston
Other
- Research Site - Clichy
Surrey
- Research Site - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
What the finished NCT00731263 record still lists
NCT00731263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which AZD8055 is the first listed.
NCT00731263 reports a single indexed study location in New York, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT00731263 about?
NCT00731263 is a clinical study titled "A Study of Tor Kinase Inhibitor in Advanced Tumors". The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.
What is the current status of trial NCT00731263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2008-07. Estimated completion is 2010-11.
What conditions does trial NCT00731263 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT00731263?
The interventions under investigation include: AZD8055 (DRUG).
Who is sponsoring clinical trial NCT00731263?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00731263 being conducted?
This trial has 4 study locations across New York, Texas, Surrey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00731263's enrollment target sits among peer trials
64 70th of 125 higher than 55 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia